BioCardia Announces Clarification and Next Steps on its Autologous CardiAMP Cell Therapy Programs streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
SUNNYVALE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announced it has finalized external review of interim data and evaluated interim efficacy results for the ongoing Phase III pivotal trial of CardiAMP® Cell Therapy for Heart Failure (CardiAMP HF, clinicaltrials.gov Identifier: NCT02438306), for which the FDA granted Breakthrough Designation fo
SUNNYVALE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today
BioCardia (BCDA) Reports Interim Efficacy Results in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
09.09.2022 - SUNNYVALE, Calif., Sept. 09, 2022 (GLOBE NEWSWIRE) - BioCardia, Inc. (NASDAQ, BCDA), today announced it will be featured as a presenting company at the H.C. Wainwright 24th Annual Global Investment Conference. The conference is being held on .